145 related articles for article (PubMed ID: 25194439)
21. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
22. HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.
Cao GD; Chen K; Xiong MM; Chen B
PLoS One; 2016; 11(8):e0161219. PubMed ID: 27536774
[TBL] [Abstract][Full Text] [Related]
23. Examination of HER3 targeting in cancer using monoclonal antibodies.
Gaborit N; Abdul-Hai A; Mancini M; Lindzen M; Lavi S; Leitner O; Mounier L; Chentouf M; Dunoyer S; Ghosh M; Larbouret C; Chardès T; Bazin H; Pèlegrin A; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):839-44. PubMed ID: 25564668
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.
Ema A; Yamashita K; Ushiku H; Kojo K; Minatani N; Kikuchi M; Mieno H; Moriya H; Hosoda K; Katada N; Kikuchi S; Watanabe M
Cancer Sci; 2014 Dec; 105(12):1591-600. PubMed ID: 25455899
[TBL] [Abstract][Full Text] [Related]
25. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
26. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
27. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Jacob W; James I; Hasmann M; Weisser M
Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
29. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
[TBL] [Abstract][Full Text] [Related]
30. Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD; Lin JK
Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
32. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
33. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
34. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
35. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
36. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
37. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study.
Makatsoris T; Tsamandas AC; Strimpakos A; Alexopoulou Z; Dionysopoulos D; Pervana S; Konstantara A; Papakostas P; Samantas E; Rallis G; Dimou A; Pentheroudakis G; Papaparaskeva K; Psyrri A; Kalogeras KT; Syrigos K; Scopa CD; Fountzilas G
Anticancer Res; 2016 Apr; 36(4):1581-90. PubMed ID: 27069134
[TBL] [Abstract][Full Text] [Related]
38. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Gaborit N; Lindzen M; Yarden Y
Hum Vaccin Immunother; 2016 Mar; 12(3):576-92. PubMed ID: 26529100
[TBL] [Abstract][Full Text] [Related]
39. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
40. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.
Zaczek A; Brandt B; Bielawski KP
Histol Histopathol; 2005 Jul; 20(3):1005-15. PubMed ID: 15944951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
